DHODH and melanoma: Based directly on the findings of White and colleagues, along with subsequent verification of DHODH-blocking activity in human and mouse cells, a Phase I/II clinical trial of leflunomide in combination with a previously studied BRAF-inhibitor was initiated and is currently underway for melanoma patients (White et al., 2013) [see also Len Zon’s account of the discovery, in this issue (Zon, 2014)].